RU2001124802A - The use of saredutant and its pharmaceutically acceptable salts for the preparation of medicines used to treat or prevent mood disorders, adaptation disorders or mixed anxiety-depressive disorders - Google Patents

The use of saredutant and its pharmaceutically acceptable salts for the preparation of medicines used to treat or prevent mood disorders, adaptation disorders or mixed anxiety-depressive disorders

Info

Publication number
RU2001124802A
RU2001124802A RU2001124802/14A RU2001124802A RU2001124802A RU 2001124802 A RU2001124802 A RU 2001124802A RU 2001124802/14 A RU2001124802/14 A RU 2001124802/14A RU 2001124802 A RU2001124802 A RU 2001124802A RU 2001124802 A RU2001124802 A RU 2001124802A
Authority
RU
Russia
Prior art keywords
disorders
saredutant
preparation
pharmaceutically acceptable
adaptation
Prior art date
Application number
RU2001124802/14A
Other languages
Russian (ru)
Other versions
RU2238726C2 (en
Inventor
Ксавье ЭМОНД-АЛЬ
Филипп СУБРИ
Режи СТЕНБЕР
Original Assignee
Санофи-Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9905338A external-priority patent/FR2792835B3/en
Application filed by Санофи-Синтелябо filed Critical Санофи-Синтелябо
Publication of RU2001124802A publication Critical patent/RU2001124802A/en
Application granted granted Critical
Publication of RU2238726C2 publication Critical patent/RU2238726C2/en

Links

Claims (7)

1. Применение саредутанта (saredutant) и его фармацевтически приемлемых солей для приготовления лекарственных продуктов, которые полезны при лечении или предупреждении любых расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств.1. The use of saredutant and its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of any mood disorders, adaptation disorders or mixed anxiety-depressive disorders. 2. Применение по п.1 при лечении или предупреждении любых расстройств настроения.2. The use according to claim 1 in the treatment or prevention of any mood disorders. 3. Применение по п.2 при лечении или предупреждении больших депрессивных расстройств.3. The use according to claim 2 in the treatment or prevention of major depressive disorders. 4. Применение по п.2 при лечении или предупреждении дистимических расстройств.4. The use according to claim 2 in the treatment or prevention of dysthymic disorders. 5. Применение по п.2 при лечении или предупреждении биполярных расстройств.5. The use according to claim 2 in the treatment or prevention of bipolar disorder. 6. Применение по п.1 при лечении или предупреждении расстройств адаптации.6. The use according to claim 1 in the treatment or prevention of adaptation disorders. 7. Применение по п.1 при лечении или предупреждении смешанных тревожно-депрессивных расстройств.7. The use according to claim 1 in the treatment or prevention of mixed anxiety-depressive disorders.
RU2001124802/14A 1999-04-27 2000-04-25 Employment of saredutant and pharmaceutically acceptable salts thereof for preparing therapeutic products useful in treatment and prevention of extensive depressive disorders RU2238726C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905338A FR2792835B3 (en) 1999-04-27 1999-04-27 USE OF SAREDUTANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF ALL MOOD DISORDERS, ADAPTATION DISORDERS OR MIXED ANXIETY-DEPRESSION DISORDERS
FR99/05,338 1999-04-27

Publications (2)

Publication Number Publication Date
RU2001124802A true RU2001124802A (en) 2003-06-20
RU2238726C2 RU2238726C2 (en) 2004-10-27

Family

ID=9544931

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001124802/14A RU2238726C2 (en) 1999-04-27 2000-04-25 Employment of saredutant and pharmaceutically acceptable salts thereof for preparing therapeutic products useful in treatment and prevention of extensive depressive disorders

Country Status (33)

Country Link
US (3) US6573281B1 (en)
EP (1) EP1173179B1 (en)
JP (1) JP2002542281A (en)
KR (1) KR20020001850A (en)
CN (1) CN1172669C (en)
AR (1) AR023597A1 (en)
AT (1) ATE234617T1 (en)
AU (1) AU764304B2 (en)
BG (1) BG65472B1 (en)
BR (1) BR0010006A (en)
CA (1) CA2370834C (en)
CZ (1) CZ294904B6 (en)
DE (1) DE60001725T2 (en)
DK (1) DK1173179T3 (en)
EE (1) EE05211B1 (en)
ES (1) ES2193065T3 (en)
FR (1) FR2792835B3 (en)
HK (1) HK1041821A1 (en)
HU (1) HUP0200969A3 (en)
IL (1) IL145269A0 (en)
MX (1) MXPA01010904A (en)
NO (1) NO20015228L (en)
NZ (1) NZ513851A (en)
PL (1) PL196479B1 (en)
PT (1) PT1173179E (en)
RU (1) RU2238726C2 (en)
SI (1) SI1173179T1 (en)
SK (1) SK285459B6 (en)
TR (1) TR200102512T2 (en)
TW (1) TWI225399B (en)
UA (1) UA69441C2 (en)
WO (1) WO2000064423A2 (en)
ZA (1) ZA200107143B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792835B3 (en) * 1999-04-27 2001-05-25 Sanofi Sa USE OF SAREDUTANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF ALL MOOD DISORDERS, ADAPTATION DISORDERS OR MIXED ANXIETY-DEPRESSION DISORDERS
US6846814B2 (en) 2000-04-06 2005-01-25 Astra Zeneca Ab Neurokinin antagonists for use as medicaments
WO2001077089A1 (en) * 2000-04-06 2001-10-18 Astrazeneca Ab New neurokinin antagonists for use as medicaments
US6903092B2 (en) 2000-04-06 2005-06-07 Peter Bernstein Naphthamide neurokinin antagonists for use as medicaments
WO2001077069A1 (en) * 2000-04-06 2001-10-18 Astrazeneca Ab Naphthamide neurokinin antagonists for use as medicaments
GB0019008D0 (en) * 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0003476D0 (en) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
FR2912057B1 (en) * 2007-02-07 2009-04-17 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR
FR2904221B1 (en) * 2006-07-31 2008-09-12 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITION CONTAINING IN ASSOCIATION SAREDUTANT AND FLUOXETINE.
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
FR2912058A1 (en) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Treatment or prevention of sexual dysfunction, e.g. lack of sexual desire or erectile dysfunction, uses neurokinin A NK2 receptor antagonist, e.g. sareductant
KR101174980B1 (en) * 2007-09-14 2012-08-17 에프. 호프만-라 로슈 아게 piperidine derivatives as NK3 receptor antagonists
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2695626B1 (en) * 1992-09-17 1994-12-02 Lebroch Yannick Cup device adaptable to a beverage container.
FR2700472B1 (en) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Synergizing association having an antagonistic effect on the NK1 and NK2 receptors.
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
FR2792835B3 (en) * 1999-04-27 2001-05-25 Sanofi Sa USE OF SAREDUTANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF ALL MOOD DISORDERS, ADAPTATION DISORDERS OR MIXED ANXIETY-DEPRESSION DISORDERS

Similar Documents

Publication Publication Date Title
HUP9700603A1 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
ATE142877T1 (en) MELATONINE DERIVATIVES FOR THE TREATMENT OF SLEEP DISORDERS AND FOR PRE-ANESTHESIA
DE60020613D1 (en) (S, S) reboxetine for the treatment of fibromyalgia and other somatoform disorders
IL143512A (en) Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus
ATE399553T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DEXTROMETHORPHAN AND QUINIDENE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
ATE269846T1 (en) N-SUBSTITUTED AMINOTETRALINES AS NEUROPEPTIDE Y Y5 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF OBESITY AND OTHER DISEASES
RU2001124802A (en) The use of saredutant and its pharmaceutically acceptable salts for the preparation of medicines used to treat or prevent mood disorders, adaptation disorders or mixed anxiety-depressive disorders
DE60132851D1 (en) Medicines for the prevention, alleviation or treatment of hypertension
DE60322075D1 (en) PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
EE05211B1 (en) Use of saredutant and its pharmaceutically acceptable salts in the preparation of medicaments useful for the treatment or prevention of mood disorders, adaptive disorders, or mixed depressive disorders.
DE69939075D1 (en) Pharmaceutical composition for the prevention and treatment of diseases associated with cell diseases of the fundus
MX9707642A (en) Pharmaceutical agents for the treatment of alzheimer's disease.
PT888114E (en) USING (+) - ALPHA- (2,3-DIMETOXYPHENYL) -1- [2- (4-FLUOROPHENYL) ETHYL] -4-PIPERIDINOMETHANOL IN THE TREATMENT OF DEPRESSIVE DISEASES AND BIPOLAR DISEASES
ATE228843T1 (en) USE OF DESOXYPEGANINE TO TREAT DRUG DEPENDENCE
BG105984A (en) Osanetant in the treatment of mood disorders
DE60107900D1 (en) Pharmaceutical composition and food for the treatment of cerebral edema
DE60306503D1 (en) STATIN THERAPY FOR IMPROVING THE MAINTENANCE OF COGNITIVE FUNCTION
ATE195876T1 (en) PURIFICATION OF A SUBSTANCE INHIBITING MÜLLER'S MIXED TUMOR AND TREATMENT OF SOME TUMORS
DE69732492D1 (en) USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEAVY DEPRESSIONS ACCOMPANIED BY ANXIETY STATES
HUT71422A (en) Use of bradykinin-antagonists for producing pharmaceutical compositions for treating virus diseases
EA200200656A1 (en) NEW THERAPEUTIC COMBINATIONS (S) -2- (BENZYLAMINOMETYL) -2,3,8,9-TETRAHYDRO-7H-1,4-DIOXIN [2,3-th] INDOL-8-SHE AND NEUROLEPTIC FOR TREATMENT OR PREVENTION OF PSYCHOLOGICAL
RU2001119471A (en) USE OF RILUZOL IN THE TREATMENT OF ACOUSTIC INJURIES
RU2001127309A (en) The use of osanetant in the manufacture of drugs useful for the treatment of mood disorders
BR9913242A (en) Use of r (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-p iperidinamethanol for the treatment of sleep disorders
RU99104703A (en) METHOD FOR TREATING LOWER JAW OSTEOMYELITIS